Grants for Nonprofits - Health

This grant provides financial support to individuals, artists, and community organizations in Worcester County to develop projects in the arts, humanities, and sciences that enhance the cultural landscape and benefit local residents.

This funding opportunity provides financial support to American Indian and Alaska Native communities to develop and implement injury prevention programs that address health disparities and reduce preventable injuries and violence.

The City of Sacramento Office of Innovation and Economic Development is offering Incubator and Accelerator Grants to fund organizations that support start-up businesses and entrepreneurs in the Sacramento region. The program's mission aligns with stimulating economic development and fostering innovation by nurturing early-stage businesses. The grant size ranges from $10,000 to $100,000, with a total allocation of approximately $500,000, and a grant duration of one year. The deadline for applications is September 9, 2024. The target beneficiaries are early-stage businesses and entrepreneurs within the Sacramento region, particularly those with high growth potential and innovative solutions. The primary impact goal is for participants of the funded incubator and accelerator programs to successfully start or grow their businesses, thereby spurring innovation and stimulating economic development locally. Non-profits and companies are invited to apply for funding to run these programs. The grant prioritizes programs that offer a comprehensive suite of services, including mentorship and coaching from experienced professionals, educational workshops on business planning and financial management, product development support, and legal and administrative assistance. Furthermore, programs should focus on marketing and branding support, strategic partnerships, and facilitating access to funding through pitch training and investor introductions. Access to shared office space is also a valuable component. Expected outcomes include a measurable increase in the number of new businesses started and existing businesses grown within the Sacramento region. The program aims to foster a vibrant entrepreneurial ecosystem, leading to job creation and economic prosperity. The City's strategic priority is to invest in initiatives that directly contribute to innovation and economic growth, with the theory of change being that by supporting early-stage businesses through comprehensive programs, they will be better equipped to succeed and contribute to the local economy. Eligible activities for grant expenditures are broad, covering program development and delivery, staff salaries, stipends for volunteers and participants, training supplies, office space, marketing, and even food for participants (up to 5% of the grant total). Scholarships for program participants, software subscription fees, and professional services are also permissible. Applicants must operate from a fixed place of business within Sacramento city limits, or provide grant-supported programming within the city, and be in compliance with current and past City grants.

The purpose of this Notice Of Funding Opportunity (NOFO) is to solicit applications on the optimization and characterization of technologies and assays with the potential for utilization and adoption in regulatory submissions of genome editing therapeutics. The NIH Somatic Cell Genome Editing (SCGE) Program is funded through the NIH Common Fund, which supports cross-cutting programs that are expected to have exceptionally high impact. All Common Fund initiatives invite investigators to develop bold and innovative approaches to address problems that may seem intractable or to seize new opportunities that offer the potential for transformation of research processes. The simplicity and broad applicability of targeted and programmable genome editing approaches, including but not limited to those based on CRISPR-Cas9, raise the possibility of a fundamentally new way to treat a variety of genetic diseases. However, many challenges need to be overcome before such techniques could be widely used in the clinic. To maximize the potential of genome editing technology, the SGCE program was developed to accelerate the translation of genome editing technology into clinical applications. Based on input received from stakeholders from academia, industry, and regulatory agencies, as well as the substantial progress in the field of genome editing since the launch of the first five-year phase of the SCGE program, the second five-year phase of SCGE will focus on translating and accelerating safe and effective somatic cell genome editing therapeutics into the clinic. Specifically, SCGE Phase 2 will support the following initiatives: 1) Technologies and Assays for Therapeutic Genome Editing INDs; 2) IND-enabling Studies of Somatic Genome Editing Therapeutic Leads; 3) IND-enabling and Platform Clinical Trials of Somatic Genome Editing for Multiple Diseases and 4) Somatic Cell Genome Editing Translational Coordination and Dissemination Center (TCDC). The SCGE Program will involve collaborative research by a consortium of award recipients with differing expertise to develop, optimize and demonstrate improved candidate genome editing therapeutics as treatments for human disease. Recipients from all four SCGE program components will form a consortium, governed by a steering committee of investigators and NIH staff that will develop consensus policies and procedures for Consortium-wide activities such as data and resource sharing. Collectively, these initiatives are intended to substantially expand the number of genetic diseases treated by in vivo genome editing, ultimately allowing this technology to achieve its potential as a therapeutic platform to treat genetic disease. Program Formation and Governance The awards funded under this NOFO will be cooperative agreements (see Section VI.2. Cooperative Agreement Terms and Conditions of Award). Close interactions among the recipients and NIH will be required to maintain this complex program. The whole SCGE Program governance will rest with the SCGE Program Steering Committee in collaboration with NIH Program Officials, with advice from Program Consultants providing critical scientific and managerial insights, and subject to oversight by the NIH SCGE Working Group. The NIH SCGE Working Group consists of NIH Programmatic Staff from multiple Institutes and Centers of the NIH as well as the Office of the Director. This group will be primarily responsible for the stewardship of the SCGE Program. The SCGE Working Group is co-chaired by the Director of the National Center for Advancing Translational Sciences (NCATS) and the Director of the National Institute for Neurological Disorders and Stroke (NINDS). It reports to the Directors of the Office of Strategic Coordination/Common Fund and the Division of Program Coordination, Planning, and Strategic Initiatives for final funding decisions. Research Objectives The purpose of this 3-year U01 NOFO is to support the optimization and evaluation of IND-enabling technologies and assays to help accelerate the clinical development and evaluation of novel somatic cell genome editing therapeutics to treat a broad array of rare and common diseases. Examples of technologies and assays that would be responsive to this NOFO include those for Chemistry, Manufacturing and Controls (CMC), potency, pharmacology/toxicity, detection and measurement of on/off-target effects, immune responses, and cell tracking studies. Applicants should have an IND-enabling technology or assay to be optimized, with supportive preliminary data, at the time of submission. Projects should focus on further development and rigorous characterization of the technology and/or assay for utilization and adoption in regulatory submissions. This NOFO is intended to bring assays to the point where they could be integrated with future clinical trials/studies. Research Scope This program will support the optimization, refinement, and establishment of acceptability criteria of technologies and assays that will provide data on the efficacy and safety of somatic cell genome editing technologies and delivery systems in future regulatory submissions. In Investigational New Drug Applications (INDs) submitted to the U.S. Food and Drug Administration (FDA), sufficient CMC information should be provided to assure safety, identity, quality, purity, and strength (including potency) of the investigational product entering clinical trials. CMC activities include the establishment of manufacturing processes and product characteristics, as well as defining product testing methods to ensure that the product is safe, effective, and consistent between batches. To guide the CMC development plan, it is important to establish the Critical Quality Attributes (CQAs), a set of criteria to which a drug product should conform to be considered acceptable for its intended use. Establishing acceptable CQAs for genome editing therapeutics can be challenging due to the biological complexity of the products. Nevertheless, the risk associated with genome editing therapies can be reduced by developing appropriate analytical procedures and assays to help define suitable CQAs and ensure high-quality clinical products that meet the quality requirements for nonclinical and clinical trial materials. Process control techniques developed for protein drug production are not always applicable to cell and gene therapies. While a few in vivo somatic cell genome editing therapeutics have entered the clinic targeting the liver and eye, a comprehensive suite of technologies and assays to help define the CQAs of the genome editing product(s) have yet to be generated. Some examples of CMC challenges during the development of genome editing products include suitable potency assays to demonstrate relevant biological activity and to help determine dosage, pertinent assays to inform editing-related immunogenicity, safety and efficacy, manufacturing procedures suitable for scale-up for a multifaceted product, and other optimized bioanalytical assays to fulfill CMC-related activities. A combination of assays may be required when a single assay may not provide adequate CMC data due to a complex mechanism of action or multiple activities of a preliminary therapeutic agent. To support the clinical advancement and regulatory approval of the ever-increasing number of genome editing therapeutics, there is a need for appropriate fit-for-purpose CMC and analytical methodologies to be optimized and qualified for eventual implementation into genome editing therapeutic programs as these programs transition from research into clinical stages. Also in 2023, the FDA Modernization Act 2.0 permits the utilization of new approach methodologies (NAMs) to animal testing, including non-animal or human biology-based test methods, such as cell-based assays, microphysiological systems, or bioprinted or computer models to predict drug toxicity, metabolism, and other absorption, distribution, metabolism, and excretion (ADME) properties. NAMs can now be used to seek FDA exemptions for assessing drug safety and effectiveness during the preclinical phase. Some applicable assays have been developed by investigators in academic laboratories or small biotechnical companies for research purposes but require adaptation and/or comprehensive analysis to meet regulatory requirements during the review of clinical products. Applications responsive to this NOFO will fill this gap as these technologies and assays are critical during preclinical development and the manufacturing process, and would impact product quality, safety and efficacy during clinical application. Successful assays and associated protocols will be shared with the broader community via the Translational Coordination and Dissemination Center (TCDC) and SCGE Toolkit that will be the primary output of this collaborative Common Fund-sponsored program. Examples of product and process characterization assays supported by this NOFO include, but are not limited to: Technologies that enable more informative assessment of patient adaptive and/or innate immune (immunogenicity) responses to genome editors and vectors during clinical trials, including the presence or development of anti-drug antibodies, potential biological consequences, and whether those responses change over time or in response to redosing New approach methodologies that complement traditional animal research, including microphysiological systems, organoids, and other 3- dimensional cell models, that recapitulate critical aspects of normal human physiology and provide quantifiable and predictive measurements of genome editing effects Computer-based technologies, for example artificial intelligence or machine learning, for generating predictive models of individual or population-based biological response(s) to genome editing-based intervention Technologies to detect on and off-target editing in gene-edited animals (or humans) in a non-invasive manner, including but not limited to the use of cell-free DNA obtained from blood or other tissue compartments that can be readily accessed non-invasively (e.g. saliva, exhaled breath condensate, urine, stool) Methods to assess or predict the potential clinical impact of undesired off-target effects, including but not limited to cytotoxicity, genotoxicity, mutagenicity and tumorigenicity potential In vitro and in vivo assays for clinically relevant evaluation of the pharmacokinetic and pharmacodynamic properties of a genome delivery or editing reagent, including durability of editing, bioavailability, bioactivity, cell/tissue specificity, and/or dose-prediction in clinical trials Potency assays to assess specificity and sensitivity measurements of the functionality and efficiency of genome editing product, including vector infectivity and identity, editor activity, and other parameters as appropriate Process development technologies for scale-up and cGMP manufacturing of genome editing products Bioanalytical methods for final product identity and potential contamination Technologies for tracking and monitoring of genome editing therapies in vivo, which may include amongst others, in utero therapeutic products Applications addressing the following topics will be deemed non-responsive and will not be reviewed: Exploratory research for new technology development that lack supporting unpublished and/or preliminary data Assays that are not applicable to genome editing INDs Discovery or development of new genome editing therapeutic products Assays/technologies for non-somatic cell editing Projects proposing clinical trials Technologies that can be broadly applicable to more than one genome editing therapeutic product and/or indication are encouraged Funds from the NIH will be made available through the U01 cooperative agreement award mechanism. Awards will be up to 3 years in duration and will include milestones to evaluate progress. During the initial two years of funding, it is expected that investigators will complete the necessary studies to establish an assay profile and performance criteria (Accuracy [Relative], Analytical Measurement Range, Parallelism, Precision, Selectivity, Specificity, and Stability, as applicable) of sufficient quality for the likely utilization of the technology or assay to support IND-submission of genome editing therapeutic products. As part of the NIH SCGE Consortium, Consortium-generated animal and/or human samples from genome-editing therapeutic studies are expected to become available, and applicants are encouraged to collaborate with other SCGE Consortium members to help evaluate the utility and performance of the assay(s). It is anticipated that in the remainder of the award period, projects will continue to perform assay optimization and further define the analytical parameters using relevant samples, including samples from other consortium members as scientifically appropriate. NIH's Interest in Diversity Every facet of the United States scientific research enterprise—from basic laboratory research to clinical and translational research to policy formation–requires superior intellect, creativity and a wide range of skill sets and viewpoints. NIH’s ability to help ensure that the nation remains a global leader in scientific discovery and innovation is dependent upon a pool of highly talented scientists from diverse backgrounds who will help to further NIH's mission. Research shows that diverse teams working together and capitalizing on innovative ideas and distinct perspectives outperform homogenous teams. Scientists and trainees from diverse backgrounds and life experiences bring different perspectives, creativity, and individual enterprise to address complex scientific problems. There are many benefits that flow from a diverse NIH-supported scientific workforce, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved or health disparity populations participate in, and benefit from health research, and enhancing public trust. NIH encourages applicants to include a diverse group of scientists in their research programs, including individuals from underrepresented backgrounds (see NOT-OD-20-031, Notice of NIH’s Interest in Diversity and NOT-OD-22-019, Reminder: Notice of NIH’s Encouragement of Applications Supporting Individuals from Underrepresented Ethnic and Racial Groups as well as Individuals with Disabilities). See Section VIII. Other Information for award authorities and regulations.

The Community Impact Arts Grant (CIAG) program, funded by the LA County Department of Arts and Culture, offers financial support ranging from $10,000 to $100,000 to nonprofit organizations and municipal departments in Los Angeles County, whose primary mission is outside of the arts, to enhance community wellbeing and solve civic problems through high-quality arts and culture programs.

This funding opportunity is designed for researchers investigating how RNA modifications affect brain aging and the development of Alzheimer's disease and related dementias, with the goal of discovering new biomarkers and drug targets.

The GrowBoston grant program offers a total of $15,000 to nonprofit organizations to support outreach and community-building events related to urban agriculture. The primary goal of this grant is to engage Boston residents more deeply in existing urban agricultural resources and broader urban agriculture activities. These events must be open to the public and focus on activities such as gardening, farming, food forest stewardship, beekeeping, henkeeping, and the consumption of locally-produced food. This initiative aligns with a mission to foster community engagement and education around sustainable food practices within urban environments, directly contributing to local food production and awareness. The target beneficiaries are Boston residents, with a particular focus on engaging them in various aspects of urban food production. The impact goals include increasing public participation in urban agriculture, enhancing community connection to local food systems, and promoting a greater understanding of sustainable living practices. The program prioritizes events that are planned for spring or summer 2024 and are specifically focused on Boston-based food production or urban agriculture. Examples of eligible events include garden-opening events, farm or food forest "open houses," and farmers market opening days, as long as they highlight urban agriculture. The expected outcomes of this grant program are a more engaged and informed Boston populace regarding urban agriculture. Measurable results could include the number of events hosted, the total attendance at these events, and the diversity of urban agriculture topics covered. While educational components are not mandatory, their inclusion would further support the program's objectives. The overarching strategic priority is to strengthen Boston's urban food ecosystem by encouraging community participation and utilizing existing resources effectively. The theory of change behind this grant program is that by funding accessible, public events focused on urban agriculture, GrowBoston can increase residents' engagement and knowledge, leading to a more robust and sustainable local food system. By supporting community-building initiatives, the program aims to cultivate a sense of collective responsibility and participation in urban food production. Allowable uses of funding include event supplies, food, non-alcoholic beverages, entertainment, and outreach materials, with up to 10% for indirect/administrative costs. This ensures that the grants directly facilitate event execution and community outreach, reinforcing the program's core objectives.

This funding opportunity provides financial support to organizations in rural areas to develop and implement programs that address behavioral health challenges among youth while promoting careers in behavioral health.

This program provides funding to tribal communities in Montana for forestry projects that enhance green spaces, improve air and water quality, and support cultural practices and climate resilience.

This funding opportunity supports nonprofit organizations, public entities, tribal nations, and educational institutions in Oklahoma to develop innovative health and wellness initiatives targeting tobacco prevention, obesity reduction, and healthcare improvements for children and seniors.

This funding opportunity supports community-based research projects that aim to improve health outcomes and reduce health disparities among minority populations through collaborative interventions.

This funding opportunity supports research that explores the effects of aging on individuals living with HIV, focusing on improving health outcomes and management strategies for this population.

Reissue of PAR-20-119. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders, substance use disorders (SUDs) or alcohol use disorder (AUD), and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged. This FOA supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. Projects seeking support for a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies should consider the companion U01 FOA.

This grant provides financial support to nonprofit organizations across the U.S. that focus on improving the lives of underprivileged children, women, animals, and the environment through innovative and effective strategies.

The GPOA Foundation is committed to enhancing the lives of children and youth within Orleans Parish, Louisiana, through substantial financial support to nonprofit organizations. With grants ranging from $10,000 to $20,000, the foundation focuses on operational costs of programs that directly benefit this demographic, including staff salaries and materials. Notably, the foundation is open to considering multi-year requests for three years of declining support, contingent on the organizations' impact objectives and evaluation plans. Moreover, collaborative grant requests involving up to three organizations are encouraged, aiming to foster a cooperative approach towards achieving common outcomes. Eligibility is restricted to nonprofits serving children and youth in Orleans Parish, and the foundation does not fund building or renovation expenses, equipment, event sponsorships, individual scholarships, or out-of-state programs. The GPOA Foundation prioritizes early childhood education, grade-level reading proficiency by the third grade, enrichment programs, special education, and vocational training for at-risk youth, with a vision to level the playing field for the most vulnerable segments of the community. Grant renewed every year. Annual Fall opening/closing concept paper deadline: October 1st to November 1st. Full application ONLY by invitation.

The Ramsey County's Critical Corridors Development & Infrastructure program is a redevelopment grant, offering $100,000 to $500,000 for projects that intensify land use, facilitate multifamily housing, improve pedestrian or bicycle infrastructure, and promote development in disinvested areas within transit, economic, and cultural corridors in Ramsey County, Minnesota.

This funding opportunity is designed to support research that gathers timely feedback from healthcare providers and the public on important immunization issues to improve vaccine recommendations and coverage strategies.

This funding opportunity supports research projects that explore and address the health disparities related to HIV and substance use among underserved racial and ethnic minority populations in the U.S.

The "Materials to Enhance Training in Experimental Rigor (METER)" grant aims to support the creation of innovative educational materials for an online platform, designed to improve understanding and application of rigorous biomedical research principles among researchers and scientists at different career stages.

This program seeks passionate individuals from diverse backgrounds to become community facilitators, leading workshops on early childhood development and equity for families with children from prenatal to age 5 in Washington.